|
TauRx Therapeutics Ltd is a life sciences/pharmaceutical company incorporated in Singapore with primary research facilities and operations in Aberdeen, Scotland.〔 〕〔 〕 The company was co-founded in 2002 by the late gynecologist, surgeon and venture capitalist K. M. Seng and Claude Wischik, Professor of Old Age Psychiatry at the University of Aberdeen, Scotland, who is currently the company's Executive Chairman. The company's protein aggregation inhibitors target the underlying pathology of dementia, with the aim of modifying or halting disease progression. Their lead compound, LMTX™, targets aggregation of tau and is believed to act on synuclein, TDP-43 and huntingtin protein. Its primary development in Alzheimer's disease is focused in its activity as a Tau Aggregation Inhibitor (TAI).〔 〕〔Wischik CM, Lai RYK, Harrington CR. Modelling prion-like processing of tau protein in Alzheimer’s disease for pharmaceutical development. In: ''Brain Microtubule Associated Proteins: Modifications in Disease'', eds. Avila J, Brandt R, Kosik KS. (1997) pp. 185-241. Amsterdam: Harwood Academic Publishers.〕〔Wischik CM, Wischik DJ, Storey JMD, Harrington CR. Rationale for tau-aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. In: ''Emerging Drugs and Targets for Alzheimer's Disease''. Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism, ed. Martinez A. (2010) pp. 210-232. Cambridge: RSC Publishing.〕〔 〕 In 1988, while at Cambridge University, Wischik and coworkers discovered that abnormal fibres of tau protein form inside nerve cells in patients with Alzheimer's disease, and that their aggregation into tau tangles correlates to the development of dementia. In 1997, Wischik and his team moved to the University of Aberdeen, where they continued their pioneering research into tau pathology and protein aggregation inhibition. In 2002, the company was formed as a spin-out of the University of Aberdeen. Rember - a first generation TAI - was used in Phase 2 clinical trials in Alzheimer's, with encouraging results announced by Wischik and colleagues in July 2008 at the Alzheimer's Association's International Conference on Alzheimer's Disease (ICAD 2008) in Chicago.〔 〕〔 〕 The Phase 2 results were published in the Journal of Alzheimer's Disease in January 2015.〔 〕 In the latter part of 2012, the company announced that it had initiated Phase 3 clinical trials with LMTXTM for mild and moderate Alzheimer's disease and behavioral variant FTD (bvFTD). In January 2015, the company announced that all three Phase 3 clinical trials were fully recruited. ==References== 〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「TauRx Therapeutics」の詳細全文を読む スポンサード リンク
|